{"product_id":"kros-vrio-analysis","title":"Keros Therapeutics, Inc. (KROS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Keros Therapeutics, Inc. (KROS)'s sustained success by diving into this essential VRIO Analysis. We distill the core findings - Value, Rarity, Inimitability, and Organization - into the critical summary found in \u0026amp;O4\u0026amp;, revealing exactly where this business's competitive edge lies. Read on to grasp the strategic implications immediately.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Takeda Global License Agreement for elritercept (KER-050)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the Takeda deal for elritercept (KER-050) as a critical inflection point for Keros Therapeutics. Honestly, this partnership is the single biggest driver of your current financial stability and strategic focus. Here’s the breakdown using the VRIO lens.\u003c\/p\u003e\n\n\u003ch\u003eValue: External Validation and Non-Dilutive Capital\u003c\/h\u003e\n\u003cp\u003eThe value here is massive, not just in the cash but in the validation from a global player like Takeda. You secured a $200 million upfront payment in February 2025, which is pure, non-dilutive funding. This immediately helped shore up the balance sheet, extending your operational runway into 2029. Also, Takeda is now shouldering the global development and commercialization load outside of Greater China, which is a huge operational lift for a company your size. The fact that dosing the first patient in the Phase 3 RENEW trial triggered an additional $10 million milestone payment shows the value is being realized right now.\u003c\/p\u003e\n\n\u003ch\u003eRarity: A Major Pharma Partnership on a Late-Stage Asset\u003c\/h\u003e\n\u003cp\u003eIt’s rare for a company at Keros Therapeutics’ stage to lock in a major pharmaceutical partner like Takeda for a late-stage asset like elritercept, especially one that is already moving into Phase 3 planning. This deal structure, securing significant upfront cash for an asset advancing in a competitive space - rivaling Bristol Myers Squibb's Reblozyl - is not common. To be fair, the early clinical data showing a response rate in the 40s for high transfusion burden MDS patients, versus the competitor’s 20%, likely made this rare opportunity too good for Takeda to pass up.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Deal Terms vs. Asset Uniqueness\u003c\/h\u003e\n\u003cp\u003eThe specific structure of the deal terms - the upfront cash, the milestone tiers, and the royalty stack - is definitely imitable if another company develops an asset showing similar promise and clinical data. However, the timing of this specific agreement, closing in January 2025, and the unique clinical profile of elritercept itself make replicating this exact financial outcome difficult for a competitor right now. The advantage isn't in the contract language; it’s in having the asset ready to go.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Capital Allocation Shift\u003c\/h\u003e\n\u003cp\u003eYour organization is clearly set up to capitalize on this. The agreement makes Takeda responsible for all development, manufacturing, and commercialization outside of the specified territories as of the effective date. This transition is reflected in your financials; R\u0026amp;D expenses declined as elritercept moved over, freeing up internal capital to focus on your wholly-owned assets like cibotercept and KER-065. For the nine months ended September 30, 2025, the deal drove revenue to $243.7 million, including the $200 million upfront and $10 million milestone, leading to a net income of $110.5 million.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the key financial structure:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment (Feb 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Phase 3 Milestone Triggered (July 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones (Development\/Commercial\/Sales)\u003c\/td\u003e\n\u003ctd\u003eExceed \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Deal Value\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.31 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from Deal (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$243.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003etemporary\u003c\/strong\u003e. You captured significant value and gained crucial time by executing this deal well. The advantage lies in the immediate financial strength and the ability to advance your other pipeline candidates, like cibotercept, which is a direct result of the deal. What this estimate hides is that the long-term advantage hinges entirely on elritercept’s ultimate success in the market against established therapies, and Takeda’s ability to execute the global strategy effectively.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eElritercept is an investigational activin inhibitor.\u003c\/li\u003e\n\u003cli\u003eFDA granted Fast Track designation for low-risk MDS.\u003c\/li\u003e\n\u003cli\u003ePhase 3 RENEW trial is evaluating transfusion-dependent anemia.\u003c\/li\u003e\n\u003cli\u003eThe deal covers worldwide rights outside mainland China, Hong Kong, and Macau.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: Update the 13-week cash flow forecast to reflect the $110.5 million net income impact from the nine-month 2025 results by end of day Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Fortress Cash Position and Extended Runway\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eFortress Cash Position and Extended Runway\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nValue: Provides operational flexibility, allowing Keros to fund operations into the first half of \u003cstrong\u003e2028\u003c\/strong\u003e even after allocating \u003cstrong\u003e$375.0 million\u003c\/strong\u003e for stockholder return. This removes immediate financing risk.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Rare in the clinical-stage biotech space to have such a long runway post-restructuring, especially with \u003cstrong\u003e$693.5 million\u003c\/strong\u003e in cash as of September 30, 2025.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Low. Competitors can raise capital, but achieving this specific balance and runway through a combination of prior financing and cost-cutting is hard to replicate quickly.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Excellent organization; the Board made the decisive move to cut \u003cstrong\u003e45%\u003c\/strong\u003e of the workforce to preserve this liquidity for core programs.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained, for now. This cash buffer allows for patient, high-quality execution on KER-065 without the pressure of constant fundraising.\n\u003c\/p\u003e\n\u003cp\u003e\nThe financial underpinning of this advantage is detailed below:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$693.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned Stockholder Return\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$375.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproved by Board\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto the first half of \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-return, based on current operating assumptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFollowing cibotercept discontinuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Cost Savings\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$17 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpected from workforce reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $53.0 million in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe organizational actions supporting the cash preservation include:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReduction of headcount by approximately \u003cstrong\u003e45%\u003c\/strong\u003e, resulting in \u003cstrong\u003e85\u003c\/strong\u003e full-time employees remaining.\u003c\/li\u003e\n\u003cli\u003eDiscontinuation of the cibotercept development program for Pulmonary Arterial Hypertension (PAH).\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses decreased to \u003cstrong\u003e$19.5 million\u003c\/strong\u003e in Q3 2025 from $49.2 million in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) expenses were \u003cstrong\u003e$10.1 million\u003c\/strong\u003e for Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing KER-065 to Phase 2 in Duchenne muscular dystrophy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Proprietary TGF-ß Biology Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e It is the source of all pipeline assets, enabling the discovery of novel protein therapeutics that modulate the transforming growth factor-beta (TGF-ß) family signaling.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs target this pathway, but Keros's specific approach to engineering ligand traps is a specialized niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The underlying science is known, but the specific engineering know-how to create molecules like elritercept is not easily copied. KER-050 (elritercept) is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-ß receptor known as activin receptor type IIA fused to the Fc domain.\u003c\/p\u003e\n\u003cp\u003eThe platform has generated multiple clinical assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eKER-050 (elritercept) is being developed for cytopenias in myelodysplastic syndromes (MDS) and myelofibrosis.\u003c\/li\u003e\n\u003cli\u003eKER-065 is being developed for neuromuscular diseases, with plans to initiate a Phase 2 trial in Duchenne muscular dystrophy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$693.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway (Post-Return)\u003c\/td\u003e\n\u003ctd\u003eInto the \u003cstrong\u003efirst half of 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on Q3 2025 operating assumptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned Capital Return\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$375.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDetermined by the Board\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from $49.2 million in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Peak U.S. Sales (KER-012)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnalyst Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization is built around this platform, though the termination of KER-012 suggests the platform's predictive power needs continuous validation. The shift in R\u0026amp;D expense responsibility for elritercept to Takeda resulted in Q3 2025 R\u0026amp;D expenses decreasing to \u003cstrong\u003e$19.5 million\u003c\/strong\u003e from \u003cstrong\u003e$49.2 million\u003c\/strong\u003e in Q3 2024, while the net loss narrowed to \u003cstrong\u003e$7.3 million\u003c\/strong\u003e in Q3 2025 from \u003cstrong\u003e$53.0 million\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It provides a stream of potential assets, but sustained advantage depends on the success of the next generation of discoveries. KER-050 (elritercept) is planned for a Phase 3 trial in first-line MDS by Takeda, and KER-012 previously had an analyst peak sales estimate of \u003cstrong\u003e$3.1 billion\u003c\/strong\u003e combined U.S. and Europe.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Composition of Matter Patents (e.g., U.S. Patent No. 11,013,785)\n\u003c\/h2\u003e\n\u003cp\u003eComposition of Matter Patents (e.g., U.S. Patent No. 11,013,785)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides legal exclusivity for the core molecules, like KER-050, until at least November 2037, protecting future revenue streams from generic competition. The value is further evidenced by the exclusive global license agreement for elritercept (KER-050) with Takeda, which delivered a \u003cstrong\u003e$200 million\u003c\/strong\u003e upfront payment and is eligible for milestones of up to \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e plus tiered annual net sales royalties. The Company's cash and cash equivalents as of September 30, 2025, were \u003cstrong\u003e$693.5 million\u003c\/strong\u003e. Research and development expenses were \u003cstrong\u003e$19.5 million\u003c\/strong\u003e for the third quarter of 2025, a decrease from \u003cstrong\u003e$49.2 million\u003c\/strong\u003e for the same period in 2024, partially due to the transition of elritercept-related R\u0026amp;D expenses to Takeda.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Number\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent No. 11,013,785\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Type\u003c\/td\u003e\n\u003ctd\u003eComposition of Matter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaims Count\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarliest Expiration Date\u003c\/td\u003e\n\u003ctd\u003eNo earlier than November \u003cstrong\u003e2037\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment Associated with Licensed Asset (KER-050)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Composition of matter patents are the gold standard in pharma IP and are difficult to obtain for novel chemical\/biological entities. The Company has an extensive intellectual property portfolio covering multiple assets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProtected Asset: KER-050 (elritercept) for cytopenias in MDS and myelofibrosis.\u003c\/li\u003e\n\u003cli\u003eProtected Asset: KER-047, an orally available small molecule ALK2 inhibitor.\u003c\/li\u003e\n\u003cli\u003eProtected Asset: KER-012 (cibotercept) for pulmonary arterial hypertension and cardiovascular disorders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very low. Competitors cannot legally make or sell the patented molecule without a license. The foundational patent protects the novel therapeutic proteins, including KER-050.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization successfully secured this foundational patent, showing competence in IP strategy to protect its wholly-owned assets. The Company reported a net loss of \u003cstrong\u003e$7.3 million\u003c\/strong\u003e in the third quarter of 2025, compared to a net loss of \u003cstrong\u003e$53.0 million\u003c\/strong\u003e in the third quarter of 2024. In 2024, Keros Therapeutics' revenue was \u003cstrong\u003e$3.55 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e2250.99%\u003c\/strong\u003e compared to the previous year's \u003cstrong\u003e$151,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is the strongest form of protection, lasting for decades unless successfully challenged. The cash position, less \u003cstrong\u003e$375.0 million\u003c\/strong\u003e determined for return to stockholders, is expected to fund operating expenses into the \u003cstrong\u003efirst half of 2028\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: KER-065 Development Program (DMD Focus)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents the primary, wholly-owned asset with potential for high, unpartnered future returns, targeting Duchenne muscular dystrophy (DMD), a market with unmet needs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many DMD candidates exist, but KER-065's specific mechanism targeting TGF-β signaling offers a differentiated approach.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can pursue similar targets, but the specific molecule and its clinical data package are unique.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization is doubling down here, planning the Phase 2 trial initiation in Q1 2026, showing clear focus.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Its advantage is contingent on positive Phase 2 data; success will make it a highly valuable, proprietary asset.\u003c\/p\u003e\n\n\u003cp\u003eKER-065 development is supported by a strong financial foundation, with cash and cash equivalents reported at \u003cstrong\u003e$720.5 million\u003c\/strong\u003e as of March 31, 2025, expected to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e. This was bolstered by a \u003cstrong\u003e$200.0 million\u003c\/strong\u003e upfront payment from the Takeda license agreement received in February 2025. Research and development expenses for Q1 2025 were \u003cstrong\u003e$48.7 million\u003c\/strong\u003e, an increase from \u003cstrong\u003e$38.3 million\u003c\/strong\u003e in Q1 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense (Q1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$720.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTakeda Upfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFebruary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Initiation Target\u003c\/td\u003e\n\u003ctd\u003eQ1 2026\u003c\/td\u003e\n\u003ctd\u003eTarget for DMD trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7MM DMD Market Size (Reported)\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e$2.15 billion\u003c\/strong\u003e and \u003cstrong\u003e$2.3 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 7MM DMD Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2033\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organizational focus and execution milestones for KER-065 include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial topline results from the Phase 1 clinical trial met key objectives for safety, tolerability, pharmacokinetics, and pharmacodynamics.\u003c\/li\u003e\n\u003cli\u003ePhase 1 data indicated KER-065 was generally well-tolerated, with no major safety signals observed to date.\u003c\/li\u003e\n\u003cli\u003ePhase 1 data showed increases in markers of muscle mass and decreases in markers of bone resorption.\u003c\/li\u003e\n\u003cli\u003eRegulatory engagement is planned for Q3 2025 or late 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 2 clinical trial initiation in DMD patients is targeted for Q1 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAnalyst sentiment reflects potential value realization contingent on clinical progression:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage one-year price target from nine analysts: \u003cstrong\u003e$29.00\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHigh estimate: \u003cstrong\u003e$41.00\u003c\/strong\u003e; Low estimate: \u003cstrong\u003e$15.00\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential upside of \u003cstrong\u003e180.74%\u003c\/strong\u003e from a reported stock price of \u003cstrong\u003e$10.33\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConsensus recommendation from 13 brokerage firms: \u003cstrong\u003e2.1\u003c\/strong\u003e ('Outperform').\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: elritercept (KER-050) Clinical Advancement Status\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProgression to Phase 3 RENEW trial for transfusion-dependent anemia in myelodysplastic syndromes (MDS). The initiation of patient dosing triggered a $10 million milestone payment from Takeda.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment (Takeda)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment Received Date\u003c\/td\u003e\n\u003ctd\u003eFebruary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Future Milestones (Takeda)\u003c\/td\u003e\n\u003ctd\u003eExceeding \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (as of 3\/31\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$720.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003ePartnered asset entering Phase 3 planning for a hematological indication. Competitive product, Reblozyl, generated $1.2 billion in revenue in the first nine months of 2024.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003ePartnership agreement effective date: January 16, 2025.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eExecution capability demonstrated by securing the Takeda deal and advancing the asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash \u0026amp; Cash Equivalents (as of 12\/31\/2024): \u003cstrong\u003e$559.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected cash runway into \u003cstrong\u003e2029\u003c\/strong\u003e when combined with the Takeda upfront payment.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the year ended 12\/31\/2024: \u003cstrong\u003e$173.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Net Income: \u003cstrong\u003e$148.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eLead time advantage in the same indication over competitors, eroding as Phase 3 progresses. The Phase 3 RENEW trial is a global, randomized, double-blind, placebo-controlled study.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Organizational Agility Post-Restructuring\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eOrganizational Agility Post-Restructuring\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to execute a \u003cstrong\u003e45%\u003c\/strong\u003e workforce reduction, saving an expected average annualized cost of \u003cstrong\u003e$17 million\u003c\/strong\u003e, demonstrates a commitment to capital efficiency and focus, which investors value highly in a volatile sector following the discontinuation of the cibotercept Pulmonary Arterial Hypertension (PAH) development program.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While workforce reductions are common, the scale and precision of the cuts - reducing headcount to \u003cstrong\u003e85 full-time employees\u003c\/strong\u003e - while retaining core R\u0026amp;D talent for other pipeline assets is a specific organizational feat following the decision to halt the TROPOS trial.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. It requires tough leadership decisions and a clear strategic mandate that many management teams struggle to implement effectively, especially when pivoting focus to remaining assets like KER-065.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e This action shows the leadership is organized to make hard choices to maximize the cash runway. As of December 31, 2024, cash and cash equivalents were \u003cstrong\u003e$559.9 million\u003c\/strong\u003e, which, combined with the \u003cstrong\u003e$200 million\u003c\/strong\u003e upfront payment from the Takeda agreement received in February 2025, is expected to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e. Based on September 30, 2024 figures plus ATM proceeds through October 31, 2024, the runway was projected into the \u003cstrong\u003ethird quarter of 2027\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It is a one-time fix; sustained advantage comes from how the leaner team performs going forward, particularly with the focus shifting to the Phase 1 neuromuscular disease program, KER-065.\n\u003c\/p\u003e\n\u003cp\u003e\nThe financial context surrounding this restructuring is detailed below:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-cibotercept PAH discontinuation announcement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Cost Savings Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom restructuring actions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemaining Full-Time Employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-restructuring headcount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$559.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrior to Takeda payment realization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTakeda Upfront Payment Received (Feb 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContributes to extended runway\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway (with Takeda payment)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eInto 2029\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBased on December 31, 2024 figures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nKey financial and operational data points related to the period leading up to and following the restructuring decisions include:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for Q3 2024: \u003cstrong\u003e$53.0 million\u003c\/strong\u003e, compared to $39.4 million in Q3 2023.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses for Q3 2024: \u003cstrong\u003e$49.2 million\u003c\/strong\u003e, up from $34.1 million in Q3 2023.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative Expenses for Q3 2024: \u003cstrong\u003e$9.8 million\u003c\/strong\u003e, up from $9.1 million in Q3 2023.\u003c\/li\u003e\n\u003cli\u003eCash \u0026amp; Cash Equivalents as of September 30, 2024: \u003cstrong\u003e$530.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Focused Pipeline Strategy (Termination of KER-012)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Eliminating the pulmonary arterial hypertension (PAH) program (KER-012) after safety signals conserved capital and management focus, preventing resource drain on a troubled asset. The TROPOS Phase 2 trial dosing was halted in stages: higher dose arms (\u003cstrong\u003e3.0 mg\/kg\u003c\/strong\u003e and \u003cstrong\u003e4.5 mg\/kg\u003c\/strong\u003e) on \u003cstrong\u003eDecember 12, 2024\u003c\/strong\u003e, and all dosing (including \u003cstrong\u003e1.5 mg\/kg\u003c\/strong\u003e and placebo) on \u003cstrong\u003eJanuary 15, 2025\u003c\/strong\u003e, culminating in the May 2025 program termination.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Decisively cutting a program based on safety data, rather than delaying, is a sign of strong governance. The decision followed observations of dose-dependent pericardial effusions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. It requires the conviction to abandon a prior investment, which is often difficult for management teams. The company is redirecting efforts to advance KER-065 for Duchenne muscular dystrophy (DMD).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The Board and management demonstrated they are organized to prioritize shareholder capital over sunk costs, a crucial governance trait. This was evidenced by immediate restructuring actions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It was a necessary action, but the advantage is the avoidance of future losses, not the creation of new value. The company expects to present topline data from the terminated TROPOS trial in \u003cstrong\u003eQ2 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe financial and operational restructuring following the KER-012 termination highlights the immediate impact on capital allocation and operational structure:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePre-Restructuring Context (Approx. Q3 2024)\u003c\/td\u003e\n\u003ctd\u003ePost-Termination\/Restructuring Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Size\u003c\/td\u003e\n\u003ctd\u003eImplied larger than 85 employees\u003c\/td\u003e\n\u003ctd\u003eReduced by \u003cstrong\u003e45%\u003c\/strong\u003e to \u003cstrong\u003e85\u003c\/strong\u003e full-time employees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Cost Savings\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eExpected average annualized savings of \u003cstrong\u003e$17 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ3 2027\u003c\/strong\u003e (as of Sep 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eExpected to fund operating expenses into \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$49.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEliminated KER-012 R\u0026amp;D spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (Sep 30, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$530.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRetained a \u003cstrong\u003e$720.5 million\u003c\/strong\u003e cash balance (Contextualized)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey organizational and governance actions taken concurrently with the KER-012 discontinuation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Strategic Committee of the Board, consisting of independent and disinterested directors, was evaluating strategic alternatives as of \u003cstrong\u003eApril 10, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company announced a C-level shakeup, with Christopher Rovaldi departing as President and COO, and CEO Jasbir Seehra taking on the role of President.\u003c\/li\u003e\n\u003cli\u003eLorena Lerner was promoted to Chief Scientific Officer.\u003c\/li\u003e\n\u003cli\u003eThe company is prioritizing its lead candidate, KER-065, for Duchenne muscular dystrophy (DMD), with Phase II DMD trials slated for the first quarter of the following year.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2024 was \u003cstrong\u003e$53.0 million\u003c\/strong\u003e, compared to a net loss of \u003cstrong\u003e$39.4 million\u003c\/strong\u003e in Q3 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKeros Therapeutics, Inc. (KROS) - VRIO Analysis: Experienced Scientific Leadership (CEO Dr. Jasbir S. Seehra)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The CEO's deep scientific background, particularly in TGF-ß biology, provides credibility for the platform and guides the strategic direction of the pipeline. This leadership was instrumental in securing the exclusive global development and commercialization license agreement for elritercept with Takeda.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many CEOs have business backgrounds; a CEO with a Ph.D. leading a platform company is less common but not unique. Dr. Seehra holds a Ph.D. in Biochemistry from the University of Southampton and completed postdoctoral work at MIT.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The specific experience and reputation of Dr. Seehra, who co-founded Acceleron Pharma, cannot be bought.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The entire scientific strategy, from discovery to the Takeda deal, flows from this leadership, showing strong alignment. Dr. Seehra became Chair of the Board effective July 1, 2024, while continuing as CEO.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Key person risk is high, but the deep, established expertise of the founder\/CEO provides a long-term anchor for the science.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The company expects its cash position, bolstered by the Takeda upfront payment, to fund operations into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial and Deal Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTakeda Upfront Cash Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Elritercept Deal Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.31 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Elritercept Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.11 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (as of 12\/31\/2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$559.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position (as of 12\/31\/2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$676.04 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$187.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eLeadership Experience and Compensation:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrior Roles included CSO at Ember Therapeutics and Co-Founder\/CSO at Acceleron Pharma Inc.\u003c\/li\u003e\n\u003cli\u003e2024 Base Salary: \u003cstrong\u003e$700,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2024 Actual Performance Bonus Paid: \u003cstrong\u003e$455,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eKeros wholly owned assets post-Takeda deal: cibotercept (KER-012) and KER-065.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Revenue: \u003cstrong\u003e$3.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516195954837,"sku":"kros-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/kros-vrio-analysis.png?v=1740188161","url":"https:\/\/dcf-model.com\/fr\/products\/kros-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}